Skip to main content

Table 1 Pedacr Response Over Time

From: PReS-FINAL-2161: Safety and effectiveness of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to <4 years or >=4 years weighing <15 kg

 

Week 24 Response Rate

N = 30

N (%)

Week 60 Response Rate

N = 20

N (%)

Pedacr 30

27 (90.0)

18 (90.0)

Pedacr 50

25 (83.3)

16 (80.0)

Pedacr 70

22 (73.3)

14 (70.0)

Pedacr 90

11 (36.7)

10 (50.0)

Back to article page

Pediatric Rheumatology

ISSN: 1546-0096